Illumina, Inc. (NASDAQ:ILMN) – Analysts at William Blair issued their Q3 2017 earnings estimates for shares of Illumina in a report released on Wednesday. William Blair analyst A. Murphy forecasts that the life sciences company will post earnings per share of $0.99 for the quarter. William Blair also issued estimates for Illumina’s Q4 2017 earnings at $1.16 EPS, Q1 2018 earnings at $1.01 EPS, Q2 2018 earnings at $1.03 EPS, Q3 2018 earnings at $1.17 EPS and Q4 2018 earnings at $1.14 EPS.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.14. The firm had revenue of $662 million during the quarter, compared to the consensus estimate of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.86 earnings per share.
Several other research analysts have also recently commented on the stock. Vetr cut shares of Illumina from a “buy” rating to a “hold” rating and set a $209.78 target price for the company. in a research report on Thursday. BidaskClub cut shares of Illumina from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Barclays PLC restated an “equal weight” rating and issued a $150.00 target price on shares of Illumina in a research report on Wednesday, August 9th. Canaccord Genuity upgraded shares of Illumina from a “hold” rating to a “buy” rating and upped their target price for the stock from $170.00 to $215.00 in a research report on Monday, August 7th. Finally, Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $177.01.
Shares of Illumina (ILMN) opened at 207.15 on Friday. The firm has a market cap of $30.24 billion, a P/E ratio of 41.56 and a beta of 0.83. The company has a 50-day moving average of $187.91 and a 200-day moving average of $177.34. Illumina has a 12 month low of $119.37 and a 12 month high of $207.49.
In related news, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $184.75, for a total value of $26,788.75. Following the completion of the sale, the senior vice president now owns 10,791 shares in the company, valued at approximately $1,993,637.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $180.24, for a total transaction of $3,604,800.00. Following the completion of the sale, the director now owns 539,176 shares of the company’s stock, valued at approximately $97,181,082.24. The disclosure for this sale can be found here. In the last 90 days, insiders sold 165,951 shares of company stock valued at $30,578,030. 1.60% of the stock is owned by insiders.
Several large investors have recently modified their holdings of ILMN. Vanguard Group Inc. increased its stake in shares of Illumina by 2.6% in the second quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock valued at $1,718,601,000 after buying an additional 255,498 shares during the period. Capital World Investors increased its stake in shares of Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after buying an additional 410,000 shares during the period. TIAA CREF Investment Management LLC increased its stake in shares of Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after buying an additional 527,548 shares during the period. Geode Capital Management LLC increased its stake in shares of Illumina by 8.0% in the first quarter. Geode Capital Management LLC now owns 1,458,071 shares of the life sciences company’s stock valued at $248,460,000 after buying an additional 107,941 shares during the period. Finally, Winslow Capital Management LLC purchased a new stake in shares of Illumina during the second quarter valued at approximately $211,584,000. Institutional investors and hedge funds own 93.32% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.